Evofem Biosciences (EVFM) Other Operating Expenses (2019 - 2026)

For the trailing twelve months through Jun 30, 2026, Other Operating Expenses at Evofem Biosciences was $11.37 million, down 20.3% year-over-year; for FY2025, it came in at $12.87 million, down 5.6% from FY2024.

• Annual Other Operating Expenses has declined for four consecutive years, with a five-year compound annual growth rate of -25.7% (FY2020 to FY2025).
• In prior years, Evofem Biosciences' Other Operating Expenses was $13.63 million in FY2024 (-25.0%), $18.18 million in FY2023 (-62.4%), $48.37 million in FY2022 (-58.7%) and $117.21 million in FY2021 (+105.9%).
• Quarterly Other Operating Expenses has run from a low of $1.44 million in Q3 2025 to a high of $31.42 million in Q3 2021 over five years.
• On a year-over-year basis, Other Operating Expenses increased in four of the last eight quarters, with an average decline of 10.0%.
• The strongest year-over-year quarter for Other Operating Expenses in the past five years was Q3 2021, with growth of 109.2%; the weakest was Q4 2022, with a decline of 72.3%.
• According to Business Quant data, Other Operating Expenses for the three prior quarters was $2.58 million (Q1 2026), $4.75 million (Q4 2025) and $1.44 million (Q3 2025).